Athira Pharma, Inc.
NASDAQ:ATHA
Overview | Financials
Company Name | Athira Pharma, Inc. |
Symbol | ATHA |
Currency | USD |
Price | 0.515 |
Market Cap | 19,930,054 |
Dividend Yield | 0% |
52-week-range | 0.412 - 4.298 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark J. Litton M.B.A., MBA, Ph.D. |
Website | https://www.athira.com |
An error occurred while fetching data.
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD